Stocksigma LogoStocksigma Logo

Natural Capsules Reports Q2FY27 Results With Operational EBITDA Growth Despite Losses

Natural Capsules reported Q2FY27 revenue of ₹51.15 cr, up 12% YoY and 5% QoQ, driven by gelatine volume expansion and steady realisations

Natural Capsules Reports Q2FY27 Results With Operational EBITDA Growth Despite Losses

Natural Capsules Ltd · Press Release · 16 Nov 2026, 2:53 am

Natural Capsules Reports Q2FY27 Results With Operational EBITDA Growth Despite Losses Natural Capsules reported Q2FY27 revenue of ₹51.15 cr, up 12% YoY and 5% QoQ, driven by gelatine volume expansion and steady realisations. EBITDA surged 440% YoY and 169% QoQ to ₹3.01 cr, with margins expanding 781 bps YoY to 5.88%. Net loss narrowed to ₹(4.22) cr versus ₹(7.03) cr in Q2FY26. H1FY27 revenue reached ₹99.86 cr with EBITDA of ₹4.13 cr. The company added Mankind Pharma, cleared a Zydus Lifesciences audit, and is restructuring its API segment ahead of planned US DMF and CEP filings.

Original exchange filing (PDF)

More announcements from Natural Capsules Ltd

All Natural Capsules Ltd announcements